james-brey / iStockphoto.com

15 September 2017Americas

Dow asks SCOTUS to review $445m award dispute

Agriculture company Dow has asked the US Supreme Court to review a dispute centring on damages for infringement of patents related to genetically engineered soybeans.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

SCOTUS rejects Dow’s $455m appeal against Bayer

5 December 2017 The US Supreme Court has refused to rule on a patent dispute between agricultural companies Dow AgroSciences and Bayer CropScience.

Biosimilars Council urges SCOTUS to limit biologics exclusivity period

22 February 2017 The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), has filed a brief in support of Sandoz’s petition for certiorari in the pending Sandoz v Amgen case.

AstraZeneca opposes Mylan’s request for SCOTUS hearing

25 November 2016 AstraZeneca and Acorda have asked the US Supreme Court not to hear an appeal from Mylan challenging a Federal Circuit ruling.

More on this story

SCOTUS rejects Dow’s $455m appeal against Bayer

5 December 2017 The US Supreme Court has refused to rule on a patent dispute between agricultural companies Dow AgroSciences and Bayer CropScience.

Biosimilars Council urges SCOTUS to limit biologics exclusivity period

22 February 2017 The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), has filed a brief in support of Sandoz’s petition for certiorari in the pending Sandoz v Amgen case.

AstraZeneca opposes Mylan’s request for SCOTUS hearing

25 November 2016 AstraZeneca and Acorda have asked the US Supreme Court not to hear an appeal from Mylan challenging a Federal Circuit ruling.

More on this story

SCOTUS rejects Dow’s $455m appeal against Bayer

5 December 2017 The US Supreme Court has refused to rule on a patent dispute between agricultural companies Dow AgroSciences and Bayer CropScience.

Biosimilars Council urges SCOTUS to limit biologics exclusivity period

22 February 2017 The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), has filed a brief in support of Sandoz’s petition for certiorari in the pending Sandoz v Amgen case.

AstraZeneca opposes Mylan’s request for SCOTUS hearing

25 November 2016 AstraZeneca and Acorda have asked the US Supreme Court not to hear an appeal from Mylan challenging a Federal Circuit ruling.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?